eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/17 | $38,000,000 | Series A |
Alexandria Real Estate Equities Alta Partners ARCH Venture Partners  Berggruen Holdings Biomatics Capital Fan Ventures Heritage Provider Network Uprising | undisclosed |
| 11/07/19 | $100,000,000 | Series B |
Alta Partners ARCH Venture Partners Biomatics Capital Fresenius Medical Care Ventures Leaps by Bayer | undisclosed |
| 03/02/21 | $125,000,000 | Series C |
Altium Capital Catalio Capital Management Farallon Capital Management HBM Healthcare Investments Invus LifeSci Venture Partners Monashee Investment Management Osage University Partners Polaris Partners Samsara BioCapital Symbiosis | undisclosed |
| 10/17/24 | $191,000,000 | Series D |
Alta Partners ARCH Venture Partners DaVita Venture Group Eisai Farallon Capital Management Fresenius Medical Care Ventures Khosla Ventures Leaps by Bayer Lux Capital NATCO Pharmaceuticals Parkwood | undisclosed |
